Application of apoptin combined peptide in preparation of medicine for treating epilepsy

By using apoptotic peptide combined with antiepileptic drugs, the problem of poor treatment effect of existing antiepileptic drugs has been solved. The apoptotic peptide combined with transmissible blood-brain barrier, acts as Hsp70 protein, and reduces the susceptibility and seizure intensity of epilepsy through the blood-brain barrier, and uses Hsp70 protein to reduce epilepsy susceptibility and seizure intensity. , improve patients' cognitive function and achieve safer and more effective treatment effects.

CN119074891APending Publication Date: 2024-12-06HARBIN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411196789.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing anti-epileptic drugs have poor results in treatment, complex pharmacokinetics, narrow treatment windows, and are prone to adverse reactions, making it difficult to effectively control epilepsy seizures and improve patients' quality of life.

Method used

The apoptotic peptide was used to connect Cy7 marker at the N-terminus to detect its distribution in vivo, and by constructing a mouse epilepsy model of hairen acid, it was verified that it could pass through the blood-brain barrier, act as Hsp70 protein, and affect the expression of AMPAR subunit. Reduce epilepsy susceptibility and seizure intensity.

Benefits of technology

The apoptotic peptide combined with the peptide significantly reduces the susceptibility and seizure intensity of epilepsy, improves the patient's spatial learning and memory ability, and has no obvious interference with mobility ability. It has good pharmacokinetic properties and effectively reaches the lesion target.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005016874660000011
    Figure HDA0005016874660000011
  • Figure HDA0005016874660000012
    Figure HDA0005016874660000012
  • Figure HDA0005016874660000021
    Figure HDA0005016874660000021
Patent Text Reader

Abstract

The invention discloses application of apoptin combined peptide in preparation of a medicine for treating epilepsy. The invention belongs to the technical field of medicine. The amino acid sequence of the apoptin combined peptide is as shown in SEQ ID NO. 1. Experiments prove that the apoptin combined peptide can significantly inhibit intracellular calcium ion concentration increase caused by epilepsy and improve the expression level of GluA2, so that the epileptic seizure strength and susceptibility are reduced, the spatial learning and memory ability of a patient is significantly improved, and the action ability of the patient is not significantly interfered. The invention provides a novel and effective technical means for treating epilepsy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a new use of apoptin combination peptides, and in particular to the use of apoptin combination peptides in treating epilepsy. The present invention belongs to the field of medical technology. Background Art

[0002] Epilepsy is a neurological disease characterized by abnormal discharges of brain neurons, which usually causes recurrent transient brain dysfunction, mainly manifested by limb convulsions, loss of consciousness, behavioral disorders and transient sensory disorders, which seriously endanger the patient's quality of life and even affect their life safety. Current research believes that factors such as neurotransmitter imbalance, ion channel dysfunction, autoimmune response and genetics are closely related to the occurrence of epilepsy, but its pathogenesis is very complex and has not yet been fully elucidated.

[0003] At present, the treatment of epilepsy is mainly based on drug control. Traditional anti-epileptic drugs, such as phenytoin sodium, carbamazepine, valproic acid, etc., have complex pharmacokinetic properties, large fluctuation range of blood drug concentration, narrow therapeutic window, and it is difficult to distinguish between therapeutic effect and toxic reaction. During the treatment process, the patient's epileptic state is often difficult to control; new anti-epileptic drugs, such as lamotrigine, levetiracetam, oxcarbazepine, topiramate, etc., although relatively safe and effective, but if used in combination with other enzyme inhibitors and enzyme inducers, they will affect their blood drug concentration, thereby affecting the efficacy and inducing adverse reactions. Therefore, it is urgent to develop a safe and effective anti-epileptic drug to control seizures, reduce adverse reactions, and improve the quality of life of patients.

[0004] Apoptin combination peptide (ADP) is an anti-tumor peptide drug composed of 44 amino acids, and its amino acid sequence is:

[0005] "Met-Gly-Arg-Lys-Lys-Arg-Arg-GIn-Arg-Arg-Arg-Leu-Lys-Pro-Pro-Ser-Lys-Lys-Arg-lle-Arg-lle-Gly-lle-Ala-Gly-lle-Thr-lle-Thr-Leu-Ser-Leu-Arg-Pro-Arg-Thr-Ala-Lys-Arg-Arg-lle-Arg-Leu" contains two nuclear localization signals at positions 82-88 and 111-121 of apoptin, a hydrophobic amino acid-rich region at positions 33-46 of apoptin, and an amino-terminal transduction peptide. Previous studies have confirmed that apoptin combination peptides inhibit the stress-induced expression of heat shock protein 70 (HSP70) protein by binding to the heat shock element of the HSP70 gene, inducing only tumor cell apoptosis without causing apoptosis of normal cells, and effectively treating gliomas. However, there are still no reports on the treatment of epilepsy with apoptin combination peptides. Summary of the invention

[0006] The purpose of the present invention is to provide a new use of apoptin combination peptide in the preparation of drugs for treating epilepsy.

[0007] In order to achieve the above object, the present invention adopts the following technical means:

[0008] The present invention first connects Cy7 to the N-terminus of the apoptin combination peptide for labeling, and detects its drug distribution in the body and whether it can penetrate the blood-brain barrier. It was found that the metabolic rate of free Cy7 in the body is significantly faster than that of the apoptin combination peptide labeled with Cy7, especially in brain tissue. After 8 hours of injection of the solution, the fluorescence signal of free Cy7 can no longer be detected in the brain tissue, but the fluorescence signal of the apoptin combination peptide labeled with Cy7 can still be detected, indicating that the apoptin combination peptide can effectively penetrate the blood-brain barrier and exist in the brain tissue for a long time to exert its drug effect. Then the present invention constructs a kainate (KA) mouse epilepsy model, and performs drug injection in groups, extracts mouse hippocampus tissue at different time points for Western Blotting (WB) detection, and detects the changes in the expression of the target protein and AMPAR subunit of the apoptin combination peptide in the hippocampus tissue in each time period, thereby verifying the therapeutic effect of the apoptin combination peptide. The results showed that after the KA mouse epilepsy model was established, the expression level of Hsp70 increased, and the expression level of AMPAR subunit GluA2 decreased, and this continued from the acute stage to the chronic stage. After injection of apoptin combination peptide for treatment, the expression level of Hsp70 was significantly reduced, and the expression level of GluA2 was increased, indicating that the apoptin combination peptide can affect Ca by acting on its target Hsp70. 2+The expression level of ion channel receptor GluA2, thereby playing a role in treating epilepsy. In addition, the present invention performs drug injection in groups one week before constructing the model, and induces epileptic seizures in mice by multiple intraperitoneal pentylenetetrazol (PTZ) one week later. By recording the number of injections required for mice to completely ignite, the ability of apoptin combination peptides and sodium valproate (VA) to reduce the susceptibility of mice to epilepsy is compared. The results show that the epilepsy susceptibility of mice can be reduced by injecting VA and apoptin combination peptides one week before PTZ induction, and the effect of apoptin combination peptides is better than that of positive drug VA. The results of electroencephalogram recording show that the intensity of epileptic seizures in mice can be reduced by injecting VA and apoptin combination peptides one week before PTZ induction, and the effect of apoptin combination peptides is better than that of positive drug VA. The present invention also extracts and cultures SD rat primary neural cells, uses KA to induce a cell epilepsy model after the primary neural cells mature, and adds apoptin combination peptides for intervention. After 24 hours, the calcium ion concentration in the primary neural cells is detected by Fluo-4 calcium ion detection method to verify the effect of apoptin combination peptides on the intracellular calcium ion level. Fluo-4 calcium ion detection results showed that the intracellular calcium ion concentration increased significantly 24 hours after KA-induced cell epilepsy model. If apoptin combination peptides were added for treatment, the increase in calcium ion concentration caused by KA induction could be reversed, indicating that apoptin combination peptides can significantly inhibit the increase in intracellular calcium ion concentration caused by epilepsy. By constructing a KA mouse epilepsy model and injecting drugs in groups, the Barnes maze was used to detect changes in the learning and memory functions of mice one month later to verify the therapeutic effect of apoptin combination peptides. The Barnes maze results showed that after 30 days of treatment with apoptin combination peptides, the time required for mice to find the target hole was significantly shortened, the number of errors was significantly reduced, and there was no significant difference in the total distance of the mice's actions, indicating that apoptin combination peptides can significantly improve the spatial learning and memory ability of epileptic mice, and have no obvious interference with the mice's ability to move.

[0009] Therefore, based on the above research, the present invention proposes the use of apoptin combination peptides in the preparation of drugs for treating epilepsy. The amino acid sequence of the apoptin combination peptides is shown in SEQ ID NO.1.

[0010] Among them, the preferred apoptin combination peptide can significantly inhibit the increase in intracellular calcium ion concentration caused by epilepsy, increase the expression level of GluA2, thereby reducing the intensity and susceptibility of epileptic seizures, significantly improving the patient's spatial learning and memory ability, and has no obvious interference with the patient's ability to move.

[0011] Preferably, the drug is an injectable drug.

[0012] Compared with the prior art, the present invention has the following beneficial effects:

[0013] The present invention provides a new use of apoptin combination peptides in the preparation of drugs for treating epilepsy. The use of apoptin combination peptides to treat epilepsy has good pharmacokinetic properties, can penetrate the blood-brain barrier, and effectively reach the lesion target; at the same time, it effectively reduces the intensity of epileptic seizures and epilepsy susceptibility, and greatly improves the cognitive dysfunction of epilepsy patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 It is the fluorescence imaging of free Cy7 and apoptin combination peptide-Cy7;

[0015] A: Representative whole-body fluorescence images of mice before, and 30 min, 4 h, 8 h, 12 h, 24 h, and 48 h after tail vein injection of Cy7-labeled ADP and Cy7 of the same molar mass; B: Representative brain tissue fluorescence imaging of mice before, and 30 min, 4 h, 8 h, 12 h, 24 h, and 48 h after tail vein injection of Cy7-labeled ADP and Cy7 of the same molar mass;

[0016] Figure 2 The expression changes of apoptin combination peptide target proteins and AMPAR subunits in KA mouse epilepsy model at different time periods;

[0017] Among them, A: The expression changes of Hsp70 and GluA2 in the hippocampus of mice with temporal lobe epilepsy at different time periods after induction of epilepsy; B: The expression changes of Hsp70 and GluA2 in the hippocampus of mice with temporal lobe epilepsy at different time periods after treatment with ADP by tail vein injection; C: The expression changes of Hsp70 in the hippocampus of mice with temporal lobe epilepsy at different time periods after induction of epilepsy, *P<0.05versus sham, **P<0.01versus sham; D: The expression changes of GluA2 in the hippocampus of mice with temporal lobe epilepsy at different time periods after induction of epilepsy *P<0.05versus sham, **P<0.01versus sham; E: The expression level changes of Hsp70 in the hippocampus of mice with temporal lobe epilepsy at different time points before and after treatment with ADP **P<0.01versus sham, #P<0.05versus KA, ##P<0.01versus KA; F: Changes in the expression level of Hsp70 in the hippocampus of mice with temporal lobe epilepsy at different time points before and after ADP treatment *P<0.05versus sham, #P<0.05versus KA, ##P<0.01versus KA;

[0018] Figure 3 Effects of apoptin combination peptide and sodium valproate on epilepsy susceptibility in PTZ mouse epilepsy model; **P<0.01versus Ctrl;

[0019] Figure 4 The effect of apoptin combination peptide and sodium valproate on the intensity of epileptic seizures in the PTZ mouse epilepsy model; **P<0.01versus PTZ, ***P<0.001versus PTZ;

[0020] Figure 5 The effect of apoptin combination peptide on calcium ion concentration in primary neural cells of SD rats induced by KA; ##P<0.01***versus KA, P<0.001versus Ctrl;

[0021] Figure 6 To test the improvement of cognitive function of KA mouse epilepsy model by apoptin combination peptides through Barnes maze;

[0022] Among them, A: heat map path trajectory of the Barnes maze experiment test phase; B: total distance moved by each group of mice in the maze; C: latency for each group of mice to find the target hole ***P<0.001versus sham, ###P<0.001versusKA; D: number of errors made by each group of mice before finding the target hole ***P<0.001versus sham, ##P<0.005versusKA. DETAILED DESCRIPTION

[0023] The present invention is further described below in conjunction with specific embodiments, but the embodiments are only used to illustrate the present invention and do not constitute any limitation to the protection scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention can be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the protection scope of the present invention.

[0024] Example 1

[0025] In this example, Cy7 was connected to the N-terminus of the apoptin combination peptide for labeling to detect its drug distribution in vivo and whether it can penetrate the blood-brain barrier.

[0026] (1) Preparation of Cy7-labeled apoptin combination peptides

[0027] The apoptin combination peptide (Met-Gly-Arg-Lys-Lys-Arg-Arg-GIn-Arg-Arg-Arg-Leu-Lys-Pro-Pro-Ser-Lys-Lys-Arg-lle-Arg-lle-Gly-lle-Ala-Gly-lle-Thr-lle-Thr-Leu-Ser-Leu-Arg-Pro-Arg-Thr-Ala-Lys-Arg-Arg-lle-Arg-Leu, i.e., shown in SEQ ID NO.1, the same below) was synthesized by Beijing Xilait Peptide Company of China through Fmoc (9-fluorenylmethoxycarbonyl) solid phase peptide synthesis (SPPS) method. Fmoc solid phase peptide synthesis is a commonly used peptide synthesis technology, which is achieved by gradually extending the polypeptide chain on a solid support (resin). The synthesized crude polypeptide is purified using high performance liquid chromatography (HPLC). The equipment used was a Varian ProStar 218HPLC system equipped with an Agilent C18 reverse phase column. The C18 column is a commonly used reverse phase chromatographic column suitable for the separation of peptides and proteins. Linear gradient elution was used during the purification process. The specific operation is as follows: Solvent A: 2% acetonitrile (ACN), 0.05% trifluoroacetic acid (TFA), Solvent B: 90% acetonitrile (ACN), 0.05% trifluoroacetic acid (TFA). The flow rate was set to 1 ml / min, and the UV detector was set at a wavelength of 220 nm to monitor the presence of peptides in the effluent. The UV detection method can detect amide bonds and aromatic groups in peptides. The purified peptide samples were subjected to mass spectrometry analysis to confirm their molecular weight and purity. The Voyager-DESTR mass spectrometer was used for analysis to accurately determine the molecular weight and structural information of the molecule.

[0028] HPLC solvent preparation for gradient elution: Solvent A: 2% acetonitrile (ACN), 0.05% trifluoroacetic acid (TFA); Solvent B: 90% acetonitrile (ACN), 0.05% trifluoroacetic acid (TFA). During the purification process, a linear gradient elution method of these two solvents was used to gradually increase the proportion of solvent B to achieve effective separation of the peptides.

[0029] (2) Tissue distribution characteristics of apoptin combination peptides

[0030] Cy7 and Cy7-labeled apoptogen combination peptide solution were dissolved in PBS buffer. Six-week-old Nu / Nu nude mice (purchased from Liaoning Changsheng Biotechnology Co., Ltd.) were injected with Cy7-labeled apoptogen combination peptide solution (3 mg / kg) through the tail vein. There were 5 mice in each group. The fluorescence signals of the whole animals and isolated organs were detected using the PE IVISSpectrum small animal living imager before injection (0 min), 30 min, 4 h, 8 h, 12 h, 24 h, and 48 h after injection. The results were analyzed using the Living image4.5.1 software supporting the PE IVISSpectrum system.

[0031] Experimental results:

[0032] The imaging results are as follows Figure 1 As shown in Figure AB, according to the experimental results, the metabolic rate of free Cy7 in the body is significantly faster than that of Cy7-labeled apoptin combination peptides, especially in the brain tissue. The fluorescence signal of free Cy7 can no longer be detected in the brain tissue 8 hours after the injection of the solution, but the fluorescence signal of Cy7-labeled apoptin combination peptides can still be detected, indicating that the apoptin combination peptides can effectively penetrate the blood-brain barrier and exist in the brain tissue for a long time to exert their pharmacological effects.

[0033] Example 2

[0034] In this example, a kainate (KA) mouse epilepsy model was constructed and drug injection was performed in groups. The hippocampal tissue of the mice was extracted at different time points for Western Blotting (WB) detection. The changes in the expression levels of the target proteins of the apoptin combination peptide and the AMPAR subunits in the hippocampal tissue at each time period were detected to verify the therapeutic effect of the apoptin combination peptide.

[0035] (1) Experimental drugs: KA was purchased from Guangzhou Shuopu Biotechnology Co., Ltd. Before use, the powder was prepared into a 0.25 mg / ml solution with PBS and filtered using a 0.22 μm microporous filter membrane.

[0036] (2) Experimental animals: C57BL / 6 male mice, weighing about 23 g, were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The experimental animals were housed in the Animal Laboratory of the School of Pharmacy, Harbin Medical University.

[0037] (3) Animal model construction: 6-8 week old male C57BL / 6 mice were injected with 1 μl (0.25 mg / ml) of kainate (KA) into the lateral ventricle under isoflurane anesthesia using a stereotaxic apparatus. The coordinates were: -0.7 mm behind the bregma, ±0.1 mm lateral, and -1.9 mm below the dura. The control group was injected with an equal dose of saline, and the behavioral changes of the mice were then closely observed. The level of epileptic seizures was determined according to the Racine scoring standard. Level 0: no convulsions. Level I: facial clonus, including rhythmic chewing, blinking, and whisker erection. Level II: neck muscle twitching with nodding movements as the main feature. Level III: unilateral forelimb clonus and twitching, but no hindlimb uprighting. Level IV: bilateral forelimb clonus and twitching accompanied by body uprighting. Level V: generalized tonic and clonic seizures, bilateral hindlimb rigidity, body dorsiflexion rigidity, and falling. Level VI: death. Rats with grade IV or V are classified as qualified experimental epileptic rats.

[0038] (4) Administration: The experiment was divided into a sham operation group (sham group), an epilepsy group (KA group), and a treatment group (KA+apoptosis combination peptide group). The apoptosis combination peptide was injected from the second day of modeling. The apoptosis combination peptide was diluted with PBS and filtered using a 0.22 μm microporous filter membrane. The injection dose was 3 mg / kg and the injection volume was 200 μl. It was injected through the tail vein 2 times a day. The brain tissues of the mice were collected for WB detection at 3, 7, 14, and 30 days after modeling or administration.

[0039] Experimental results:

[0040] WB test results Figure 2 As shown in Figure AF, according to the experimental results, after the KA mouse epilepsy model was established, the expression level of Hsp70 increased, and the expression level of AMPAR subunit GluA2 decreased, and it lasted from the acute stage to the chronic stage. After the injection of apoptin combination peptide for treatment, the expression level of Hsp70 was significantly reduced, and the expression level of GluA2 was increased, indicating that the apoptin combination peptide can affect Ca by acting on its target Hsp70. 2+ The expression level of ion channel receptor GluA2, thereby playing a role in treating epilepsy.

[0041] Example 3

[0042] In this example, the mice were divided into groups for drug injection one week before model establishment, and epileptic seizures were induced in mice by multiple intraperitoneal pentylenetetrazol (PTZ) one week later. The number of injections required for the mice to be completely ignited was recorded to compare the ability of apoptin combination peptide and sodium valproate (VA) to reduce the epilepsy susceptibility of mice.

[0043] (1) Experimental drugs: Sodium valproate (VA) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. and injected intraperitoneally once a day one week before inducing epilepsy. The injection dose was 200 mg / kg each time and the injection volume was 200 ul. It was diluted with saline and filtered through a 0.22 μm microporous membrane. The apoptosis peptide combination was diluted with PBS and filtered through a 0.22 μm microporous membrane. The injection dose was 3 mg / kg and the injection volume was 200 μl. It was injected through the tail vein twice a day one week before inducing epilepsy. Pentylenetetrazol (PTZ) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. and diluted according to the weight of the mouse. The injection dose was 10 mg / kg each time and the injection volume was 200 ul. It was diluted with saline and filtered through a 0.22 μm microporous membrane. All injection drugs were prepared before use.

[0044] (2) Experimental animals: C57BL / 6 mice, male, weighing about 23 g, were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The experimental animals were raised in the animal laboratory of the School of Pharmacy, Harbin Medical University. The experimental groups were PTZ group, VA+PTZ group and apoptin combination peptide+PTZ group, with 5 mice in each group.

[0045] (3) Inducing epilepsy: Use pentylenetetrazol (10 mg / kg) for intraperitoneal injection every 10 minutes. The level of epileptic seizure is determined according to the Racine scoring standard, level 0: no convulsion. Level I: Facial clonus, including rhythmic chewing, blinking, whisker erection, etc. Level II: Neck muscle twitching with nodding movements as the main feature. Level III: Clonus and convulsions of unilateral forelimbs, but no hind limb uprightness. Level IV: Clonus and convulsions of bilateral forelimbs accompanied by body uprightness. Level V: Generalized tonic and clonic seizures, rigidity of bilateral hind limbs, rigidity of body dorsiflexion, and falling. Level VI: Death. Mice reaching level IV or above are considered to be completely ignited. Repeat the injection until all mice are ignited, and record the number of injections for each mouse.

[0046] Experimental results:

[0047] The results of the PTZ ignition experiment are as follows Figure 3 As shown, according to the experimental results, the epilepsy susceptibility of mice can be reduced by injecting VA and apoptin combination peptide one week before PTZ induction, and the effect of apoptin combination peptide is better than the positive drug VA.

[0048] Example 4

[0049] In this example, the mice were divided into groups for drug injection one week before model establishment, and epileptic seizures were induced in mice by multiple intraperitoneal pentylenetetrazol (PTZ) one week later. The number of injections required for the mice to be completely ignited was recorded to compare the ability of apoptin combination peptide and sodium valproate (VA) to reduce the epilepsy susceptibility of mice.

[0050] (1) Experimental drugs: Sodium valproate (VA) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. and injected intraperitoneally once a day one week before inducing epilepsy. The injection dose was 300 mg / kg each time and the injection volume was 200 ul. It was diluted with saline and filtered through a 0.22 um microporous membrane. The apoptosis peptide combination was diluted with PBS and filtered through a 0.22 um microporous membrane. The injection dose was 3 mg / kg and the injection volume was 200 μl. It was injected through the tail vein twice a day one week before inducing epilepsy. Pentylenetetrazol (PTZ) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. and diluted according to the weight of the mouse. The injection dose was 60 mg / kg each time and the injection volume was 200 ul. It was diluted with saline and filtered through a 0.22 um microporous membrane. All injection drugs were prepared before use.

[0051] (2) Experimental animals: C57BL / 6 male mice, weighing about 23 g, were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The experimental animals were raised in the animal laboratory of the School of Pharmacy, Harbin Medical University. The experimental groups were PTZ group, VA+PTZ group and apoptin combination peptide+PTZ group, with 8 mice in each group.

[0052] (3) Inducing epilepsy and recording EEG: Pentylenetetrazol (60 mg / kg) was injected intraperitoneally, and the EEG of each group of mice was recorded using the BL-420 biofunctional experimental system.

[0053] Experimental results:

[0054] The results of EEG recordings are as follows Figure 4 As shown, according to the experimental results, the injection of VA and apoptin combination peptide one week before PTZ induction can reduce the intensity of epileptic seizures in mice, and the effect of apoptin combination peptide is better than the positive drug VA.

[0055] Example 5

[0056] In this example, primary neural cells from SD rats were extracted and cultured, and after the primary neural cells matured, a cell epilepsy model was induced using KA, and apoptin combination peptides were added for intervention. After 24 hours, the intracellular calcium ion concentration of the primary neural cells was detected by the Fluo-4 calcium ion detection method to verify the effect of the apoptin combination peptides on the intracellular calcium ion level.

[0057] (1) Experimental drugs: Kainic acid (KA) was purchased from Guangzhou Shuopu Biotechnology Co., Ltd. Before use, the powder was diluted with PBS to make a 1 mg / ml solution, and filtered through a 0.22 um microporous membrane. The apoptosis peptide combination was diluted with PBS and filtered through a 0.22 um microporous membrane to make a 2 mg / ml solution.

[0058] (2) Extraction of primary neural cells: 1) Animal dissection and brain tissue sampling: The experimental animals were euthanized (such as CO2 asphyxiation or cervical dislocation after anesthesia), and the craniotomy was performed under sterile conditions to remove the brain and peel off the hippocampal tissue of the brain. 2) Tissue dissociation: The removed brain tissue was washed in ice-cold HBSS, and the tissue was cut into small pieces using scissors. The cut tissue pieces were transferred to a test tube containing trypsin and digested at 37°C for 15 minutes. Gently blow the tissue pieces to help the tissue dissociate into single cells. 3) Cell separation: DNase I was added to reduce cell aggregation, and the cell suspension was filtered through a 70μm filter to remove incompletely dissociated tissue pieces. The cell suspension was centrifuged (800rpm, 5 minutes), the supernatant was removed, and the cell pellet was retained. 4) Cell resuspension and counting: The cell pellet was resuspended in an appropriate amount of neural culture medium, and the cells were counted using a Counterstar cell counting system to determine cell density and viability. 5) Cell culture: Use poly-lysine or poly-D-lysine to coat the cell culture dish or culture flask to improve cell attachment, inoculate the counted cell suspension into the coated culture dish at an appropriate density, add an appropriate amount of neural culture medium (containing B27 supplement and an appropriate amount of antibiotics), and place the culture dish in a 37°C, 5% CO2 incubator for culture. 6) Cell maintenance: Observe cell growth regularly, and usually change the culture medium every day or every other day.

[0059] (3) Administration: After the primary neurons matured (10-14 days), the culture medium was replaced. KA (100 μM) was added to the KA group to induce a cell epilepsy model. KA (100 μM) was added to the KA+apoptin combination peptide group for induction for 24 hours. The culture medium was then replaced and apoptosis combination peptide (20 ug / ml) was added for 24 hours. Fluo-4 calcium ion detection was then performed.

[0060] (4) Fluo-4 calcium ion detection: Required reagents: 1) 2mM Fluo-4, AM (DMSO) reagent solution, dissolve 1mg of Fluo-4, AM in 442μL DMSO; 2) Pluronic F127; Hanks balanced salt solution (HBSS) 3) HEPES buffer saline (10mM HEPES, 1mM Na2HPO4, 137mM NaCl, 5mM KCl, 1mM CaCl2, 0.5mM MgCl2, 5mM glucose, 0.1% BSA, pH 7.4).

[0061] Experimental steps: 1) Add 16.5 mg of Pluronic F127 to the Fluo-4, AM / DMSO solution. Pluronic F127 can prevent Fluo-4, AM from aggregating in HBSS buffer and help it enter cells. 2) Dilute the Fluo-4, AM solution with HBSS buffer to prepare a 4 μM Fluo-4, AM solution. 3) Add the prepared Fluo-4, AM solution to the cells and culture at 37°C for about 20 minutes. 4) Add 5 times the volume of HBSS buffer containing 1% fetal bovine serum and continue to culture for about 40 minutes. 5) Wash the cells three times with HEPES buffer saline, then resuspend the cells with HEPES buffer saline to prepare a 1×105 cells / mL solution. 6) Culture at 37°C for about 10 minutes, and then perform fluorescent calcium ion detection on the cells (fluorescence wavelength: excitation wavelength 494nm, emission wavelength 516nm).

[0062] Experimental results:

[0063] Fluo-4 calcium ion detection results Figure 5 As shown, according to the experimental results, the intracellular calcium ion concentration increased significantly 24 hours after the KA-induced cell epilepsy model was used. If the apoptin combination peptide was added for treatment, the increase in calcium ion concentration induced by KA could be reversed, indicating that the apoptin combination peptide can significantly inhibit the increase in intracellular calcium ion concentration caused by epilepsy.

[0064] Example 6

[0065] In this example, a KA mouse epilepsy model was constructed and the mice were divided into groups for drug injection. One month later, the changes in the learning and memory functions of the mice were detected by the Barnes maze, thereby verifying the therapeutic effect of the apoptin combination peptide.

[0066] (1) Experimental drugs: Kainic acid (KA) was purchased from Guangzhou Shuopu Biotechnology Co., Ltd. Before use, the powder was diluted with PBS to make a 0.25 mg / ml solution and filtered through a 0.22 um microporous membrane. The apoptosis peptide combination was diluted with PBS and filtered through a 0.22 um microporous membrane. The injection dose was 3 mg / kg and the injection volume was 200 μl. It was injected through the tail vein 2 times a day one week before inducing epilepsy.

[0067] (2) Experimental animals: C57BL / 6 male mice, weighing about 23 g, were purchased from Liaoning Changsheng Biotechnology Co., Ltd. The experimental animals were raised in the Animal Laboratory of the School of Pharmacy, Harbin Medical University. The experimental groups were sham group, KA group and KA+apoptosis peptide combination group, with 6 mice in each group.

[0068] (3) Animal model construction: 6-8 week old male C57BL / 6 mice were injected with 1 μl (0.25 mg / ml) of kainate (KA) into the lateral ventricle under isoflurane anesthesia using a stereotaxic apparatus. The coordinates were: -0.7 mm behind the bregma, ±0.1 mm lateral, and -1.9 mm below the dura. The control group was injected with an equal dose of saline, and the behavioral changes of the mice were then closely observed. The level of epileptic seizures was determined according to the Racine scoring standard. Level 0: no convulsions. Level I: facial clonus, including rhythmic chewing, blinking, and whisker erection. Level II: neck muscle twitching with nodding movements as the main feature. Level III: unilateral forelimb clonus and twitching, but no hindlimb uprighting. Level IV: bilateral forelimb clonus and twitching accompanied by body uprighting. Level V: generalized tonic and clonic seizures, bilateral hindlimb rigidity, body dorsiflexion rigidity, and falling. Level VI: death. Rats with grade IV or V are classified as qualified experimental epileptic rats.

[0069] (4) Administration: The experiment was divided into a sham operation group (sham group), an epilepsy group (KA group) and a treatment group (KA + apoptin combination peptide group). Apoptin combination peptide injection treatment was performed starting from the second day of modeling. The apoptin combination peptide was diluted with PBS and filtered using a 0.22 um microporous filter membrane. The injection dose was 3 mg / kg, and the injection volume was 200 μl. It was injected through the tail vein 2 times a day. The Barnes maze test was performed 30 days after modeling or administration.

[0070] (5) Barnes maze experiment: 1) Maze design: The experiment used a disc with a diameter of 100 cm, with 20 evenly spaced holes on it. One hole leads to a dark box (target hole), and the remaining holes lead to an area with no exit. The experimental environment is kept quiet, the temperature and humidity are stable, there is a strong light above the maze, and strong winds are given to encourage animals to find a way to escape to the dark box. 2) Animal preparation: The experimental animals should be adapted for a certain period of time before the experiment. The animals should be fasted for 8 hours before the experiment to increase their motivation for the dark box (target hole). 3) Adaptation stage: Before the experiment officially begins, the animals are given several days to adapt to the maze environment, but they are not allowed to find the target hole. Each adaptation time is about 5-10 minutes. 4) Training phase: The animal is placed at the starting position in the center of the maze. Usually, an obstruction is used to temporarily restrict its movement. The obstruction is removed and the timing is started. The animal will look for an escape path on the maze. When the animal finds the target hole and enters the dark box, the timing is stopped. If the animal fails to find the target hole within 3 minutes, it is guided to the target hole and allowed to stay for a few minutes to enhance memory. The training lasts for 6 days in total. 5) Testing phase: Repeat the training phase, but do not provide any guidance to see if the animal can find the target hole independently. Record the time it takes for the animal to find the target hole, the length of the path, and the number of errors (i.e., the number of times it enters the wrong hole).

[0071] (4) Data analysis: SuperMaze software was used to record the mouse experimental process, and Prism was used to perform statistical analysis on the results.

[0072] Experimental results:

[0073] Barnes maze results Figure 6 As shown in Figures AD, according to the experimental results, after 30 days of treatment with the apoptin combination peptide, the time required for mice to find the target hole was significantly shortened, the number of errors was significantly reduced, and there was no significant difference in the total distance traveled by the mice, indicating that the apoptin combination peptide can significantly improve the spatial learning and memory ability of epileptic mice and has no obvious interference with the mice's mobility.

Claims

1. Use of an apoptin combination peptide in the preparation of a drug for treating epilepsy, wherein the amino acid sequence of the apoptin combination peptide is shown in SEQ ID NO.

1.

2. The use according to claim 1, characterized in that The apoptin combination peptide can significantly inhibit the increase in intracellular calcium ion concentration caused by epilepsy, increase the expression level of GluA2, thereby reducing the intensity and susceptibility of epileptic seizures, significantly improving the patient's spatial learning and memory ability, and has no obvious interference with the patient's ability to move.

3. The use according to claim 1, characterized in that The medicine is an injectable medicine.